CRBU

CRBU

USD

Caribou Biosciences Inc. Common Stock

$2.090+0.070 (3.465%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$2.020

Hoch

$2.120

Tief

$1.930

Volumen

1.29M

Unternehmensfundamentaldaten

Marktkapitalisierung

194.6M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

2.19M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $0.66Aktuell $2.090Hoch $3.535

Ähnliche Nachrichten

GlobeNewswire

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the

Mehr anzeigen
Caribou Biosciences to Participate in Upcoming Investor Conferences
GlobeNewswire

Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with longer-term follow-up on

Mehr anzeigen
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
GlobeNewswire

Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma

BERKELEY, Calif., Nov. 02, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it will hold a webcast

Mehr anzeigen
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma